• BB Biotech’s third-quarter 2026 net profit fell 61% year over year to CHF 175.04 million.
• Net profit for the first nine months of 2026 rose year over year to CHF 604.82 million.
• During the third quarter, 12 new positions were added while eight holdings were fully sold.
• About CHF 280 million in takeover proceeds was reinvested during the quarter, while three portfolio companies secured US drug approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BB Biotech AG published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.